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RITUXIMAB IS SUCCESSFUL IN AN HIV-POSITIVE
PATIENTWITHMuSKMYASTHENIAGRAVIS
There exists almost no literature on how to treat my-
asthenia gravis (MG) in HIV-infected patients. We
report a 21-year-old HIV African woman (A3
Centers for Disease Control and Prevention staging)
who developed a bulbar form of MG concomitant
with significant CD4 T-cell increase on highly ac-
tive antiretroviral therapy (HAART) and who was
eventually successfully treated by rituximab.
This case report provides Class IV evidence that
treatment with IV rituximab (2 cycles of 1 g each)
was associated with improvement in clinical signs of
MG in an HIV-positive patient with MuSK MG.
Case report. In April 2003, the patient started HIV
treatment with zidovudine, lamivudine, and efa-
virenz. Although HIV viral load became undetect-
able, immune restoration was slow. In 2005,
zidovudine was switched to tenofovir. Within 8
months, she showed a marked increase (235%) in
CD4 lymphocyte cell count (from 244 to 575/
mm3) (figure). Concomitant with this count peak,
the patient presented with intermittent diplopia, eye-
lid ptosis, dysarthria, dysphagia, and fatigue in the
upper limbs (MG composite score; figure). Clinical
examination revealed lymphadenopathy, symmetric
ptosis, weakness, and fatigability involving the facial,
pharyngeal, palatal, tongue, neck, shoulder abductor,
and respiratory muscles. A 3-Hz repetitive facial
nerve stimulation showed a significant decrement at
34% (normal 10%). Anti-acetylcholine receptor
(AChR) antibodies were absent but antibodies
against muscle-specific tyrosine kinase (MuSK) were
positive at 1.6 nmol/L (normal 0.05 nmol/L), es-
tablishing the diagnosis of MuSK-MG.
Routine blood tests, serum immunity markers,
and serum anti-toxoplasma, varicella zoster virus,
herpes simplex virus, and cytomegalovirus antibodies
were normal or negative. Pyridostigmine, pred-
nisone, and thymectomy (without histologic abnor-
malities) did not alter the clinical course over the
following 12 months. The response to IV immuno-
globulin infusions was poor but plasma exchange
(PLEX, 3 or 5 exchanges) improved the bulbar symp-
toms dramatically, but for less than 10 days. At
1-year follow-up, anti-MuSK antibodies showed
similar serum titles, despite therapy with prednisone
(0.5 mg/kg/day), mycophenolate mofetil (1 g/day),
Figure Evolution of clinical and laboratory findings over time
Left scale: CD4 T-cell count; right scale: anti-MuSK antibody title (, normal 0.05 nmol/L). HAART  highly active
antiretroviral therapy (2 when zidovudine was switched to tenofovir, see text); IVIg  IV immunoglobulin; PLEX  plasma
exchange.
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and 3 PLEX on a bimonthly basis. In January 2009,
4 weekly IV cycles of 375 mg/m2 of rituximab were
administered and a clear clinical improvement was
documented within 10 days, followed by a rapid mo-
tor worsening following the next 2 weeks, causing
PLEX to be resumed. It was decided to administrate
2 additional cycles of 1 g of rituximab on a 2-week
interval. Shortly after the second infusion, the pa-
tient improved, with a complete regression of all her
neurologic signs. At the time of manuscript submis-
sion, 11 months later, she was in good health and
had no abnormal signs, and was on usual HAART,
prednisone 5 mg qd, and mycophenolate mofetil (1 g
qd). HIV viral load was undetectable, CD4 T cells
were at 660/L, B-cell count (CD20) was 3/L,
and anti-MuSK antibodies were 0.65 nmol/L.
Discussion. Our case presents several salient fea-
tures. First, we describe the initial HIV-infected pa-
tient with MuSK-MG who improved with
rituximab. The few patients with MG who were also
HIV reported so far had a milder course, and only
one had MuSK-MG.1 Small series in HIV-negative
patients presenting with refractory MG have sug-
gested that rituximab was beneficial.2 Thus, our pa-
tient responding only to PLEX, we opted for
rituximab, a choice that was decisive in her improve-
ment, suggesting that the overall treatment approach
for MuSK-MG is likely to be similar regardless of
HIV status.
Second, our observation may provide some insights
on the poorly known pathogenesis of MuSK-MG. In-
deed, the disease becamemanifest concomitantly with a
marked increase in CD4T cells, suggesting these cells
may play a triggering role in the disease. Supporting this
hypothesis, anHIV patient with AChR-MG improv-
ing in parallel with the progression of HIV infection
and consequent CD4 T-lymphocyte reduction has
been reported.3
Third, although we cannot rule out that HIV in-
fection and MuSK-MG occurred coincidentally,
HIV frequently causes autoimmune dysregulation
with loss of self tolerance and increased autoimmun-
ity.4 A dysfunction in regulatory T cells may also
have been at play. Indeed, this phenomenon has been
observed in HIV patients with MG,5 as well as in
HIV patients with immune reconstitution inflam-
matory syndrome (IRIS).6 Our patient presented
some IRIS features, i.e., a brisk increase in the
CD4 T-cell count and symptoms consistent with
an inflammatory process. Regardless of whether this
patient had IRIS, the brisk rise in CD4 T cells,
possibly associated with a dysfunction of regulatory
T cells, was likely instrumental in unmasking the
MuSK-MG. Rituximab may have been crucial not
only by decreasing the secretion of pathogenic auto-
antibodies, but also by impeding autoantigen presen-
tation by B cells to T cells.7
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